IMBDX Announces Performance of Multi-Cancer Screening Test Using Blood at ESMO
Over 80% Sensitivity in Hard-to-Treat Cancers Without Standard Screening, Including Pancreatic and Ovarian Cancer
Precision medicine company IMBDX announced on the 9th that it will present research results using its multi-cancer screening service, 'CancerFind,' at the '2024 European Society for Medical Oncology (ESMO)' conference held in Spain from the 13th to the 17th.
CancerFind, developed by IMBDX, is an innovative product that can detect multiple cancers (currently 8 cancer types) at an early stage with a simple blood test, significantly contributing to reducing the economic burden of cancer treatment and increasing patient survival rates.
At ESMO, the performance of CancerFind for eight major cancers, including colorectal cancer, stomach cancer, liver cancer, pancreatic cancer, lung cancer, breast cancer, ovarian cancer, and prostate cancer, will be revealed. Through an AI algorithm with significantly improved analytical performance compared to existing methods, the efficiency of analyzing cancer genomic data has been greatly enhanced. This lays the foundation for screening a broader range of cancer types beyond the current eight. By achieving sensitivities of 80.6% and 84.7% for pancreatic and ovarian cancers, respectively?cancers that lack standard screening tests and are difficult to detect early with poor prognosis?it is expected to present new possibilities for treating these cancers.
Kim Taeyu, CEO of IMBDX, stated, "Early detection of cancer is a crucial factor in increasing the survival rate of cancer patients," and explained, "Ultimately, we are strengthening product competitiveness to enable early detection of more than 26 cancers with a single blood test." He added his aspiration, saying, "We will secure the golden time for treating intractable cancers and contribute to the promotion of public health."
Given the intense market interest in early cancer screening, this presentation is expected to be a great opportunity to showcase IMBDX's potential through the excellent performance of CancerFind, positively impacting not only the academic community but also global market entry.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
